4.5 Article

Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2018.01.020

关键词

Cephalosporins; Challenges; Cross-reactivity; Immediate reactions; Penicillins; Skin tests; Tolerability

资金

  1. MURST, (Italian) Ministry for University, Scientific and Technological Research

向作者/读者索取更多资源

BACKGROUND: Studies performed since 1990 on samples of at least 30 subjects with a documented IgE-mediated hypersensitivity to penicillins have found a rate of positive responses to allergy tests with cephalosporins ranging from 0% to 27%. OBJECTIVE: We sought to assess the cross-reactivity with cephalosporins and evaluate the possibility of using cephalosporins in penicillin-allergic subjects. METHODS: We conducted a prospective study of 252 consecutive subjects who had suffered 319 immediate reactions (mostly anaphylaxis) to penicillins and had positive skin tests to at least 1 penicillin reagent. All patients underwent serum specific IgE assays for cefaclor, as well as skin tests with 3 aminocephalosporins (cephalexin, cefaclor, and cefadroxil), cefamandole, cefuroxime, ceftazidime, ceftriaxone, cefotaxime, and cefepime. Patients with negative results for the last 5 cephalosporins were challenged with cefuroxime axetil and ceftriaxone; those with negative results for aminocephalosporins were also challenged with cefaclor and cefadroxil. RESULTS: Ninety-nine participants (39.3%) had positive allergy tests for cephalosporins. Specifically, 95 (37.7%) were positive to aminocephalosporins and/or cefamandole, which share similar or identical side chains with penicillins. All 244 subjects who underwent challenges with cefuroxime axetil and ceftriaxone tolerated them. Of the 170 patients who underwent aminocephalosporin challenges, 3 reacted to cefaclor and 4 to cefadroxil. CONCLUSIONS: Cross-reactivity between penicillins and cephalosporins seems to be mainly related to side chain similarity or identity. Subjects with an IgE-mediated hypersensitivity to penicillins could be treated with cephalosporins such as cefuroxime and ceftriaxone that have side-chain determinants different from those of penicillins and are negative in pretreatment skin testing. (C) 2018 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Allergy

Hypersensitivity reactions to iodinated contrast media in Italy: a retrospective study. Characteristics of patients and risk factors

S. Voltolini, V Cofini, F. Murzilli, D. Bignardi, M. Borro, M. Calamari, C. Caruso, G. Cittadini, M. Contatore, G. Cortellini, G. Desideri, C. Di Paolo, D. Lippolis, M. Lobene, G. Manzotti, E. Meucci, S. Necozione, G. A. Ramirez, G. A. Rollandi, M. R. Yacoub, M. B. Bilo

Summary: This study describes the characteristics of Italian patients experiencing hypersensitivity reactions to iodinated contrast media and investigates potential risk factors. Male gender and age over 65 were identified as protective factors, while cardiovascular disease, respiratory allergy, and adverse drug reactions were identified as risk factors for these reactions.

EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Article Allergy

EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

Ioana Agache, Dario Antolin-Amerigo, Frederic de Blay, Cristina Boccabella, Cristiano Caruso, Pascal Chanez, Mariana Couto, Ronina Covar, Serge Doan, Jean-Luc Fauquert, Gail Gauvreau, Alina Gherasim, Ludger Klimek, Catherine Lemiere, Parameswaran Nair, Inigo Ojanguren, David Peden, Luis Perez-de-Llano, Oliver Pfaar, Carmen Rondon, Maia Rukhazde, Joaquin Sastre, Johannes Schulze, Diana Silva, Susan Tarlo, Sanna Toppila-Salmi, Jolanta Walusiak-Skorupa, Stefan Zielen, Ibon Eguiluz-Gracia

Summary: Allergic asthma is a common asthma phenotype that requires IgE sensitization to aeroallergens for diagnosis. However, current protocols for bronchial allergen challenge are not suitable for moderate-to-severe asthmatics or clinical practice. Correct diagnosis of allergic asthma can aid in selecting patients for immunomodulatory therapies, such as allergen sublingual immunotherapy.

ALLERGY (2022)

Article Dermatology

Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients

Andrea Chiricozzi, Niccolo Gori, Lucia Di Nardo, Flaminia Antonelli, Cristiano Caruso, Giacomo Caldarola, Laura Calabrese, Cristina Guerriero, Clara De Simone, Ketty Peris

Summary: Atopic dermatitis localization in exposed areas and persistence in head/neck may have a negative impact on certain treatment response parameters to dupilumab therapy.

DERMATOLOGY (2022)

Letter Medicine, General & Internal

Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization

Maurizio Gabrielli, Giulia Pignataro, Marcello Candelli, Marta Sacco Fernandez, Martina Bizzarri, Alessandra Esperide, Francesco Franceschi

INTERNAL AND EMERGENCY MEDICINE (2022)

Article Allergy

Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity

Cristiano Caruso, Colantuono Stefania, Gabriele Ciasca, Umberto Basile, Riccardo Di Santo, Diego Bagnasco, Giovanni Passalacqua, Marco Caminati, Schiappoli Michele, Gianenrico Senna, Enrico Heffler, G. Walter Canonica, Nunzio Crimi, Rossella Intravaia, Corso De Eugenio, Davide Firinu, Antonio Gasbarrini, Stefano R. Del Giacco

Summary: This retrospective study evaluated the prevalence of SE-IgE sensitization in a multicentric Italian cohort of severe asthmatic patients. SEB-IgE sensitization was found to be associated with female gender and comorbidities such as CRS and CRSwNP. No significant associations were observed between SEB-IgE sensitization and atopy, exacerbations, and corticosteroid dosages. Patients with SEB-IgE sensitization were younger and had an earlier disease onset, suggesting that it may be an independent risk factor for developing asthma.

ALLERGY (2023)

Article Medicine, General & Internal

High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study

Vitaliano Nicola Quaranta, Silvano Dragonieri, Maria Rosaria Vulpi, Nunzio Crimi, Claudia Crimi, Pierachille Santus, Francesco Menzella, Corrado Pelaia, Giulia Scioscia, Cristiano Caruso, Elena Bargagli, Nicola Scichilone, Giovanna Elisiana Carpagnano

Summary: This study found a correlation between eosinophilic inflammation and the localization of bronchiectasis in a population with severe asthma and bronchiectasis. Patients with eosinophil counts > 1000 cells/μL were more likely to have lower pulmonary bronchiectasis compared to upper lobes.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Allergy

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Gianenrico Senna, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Maria D'Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Alessandra Vultaggio, Sara Rizzoli, Alessandro Zullo, Silvia Boarino, Marilena Palmisano, Alessandra Rossi, Gianfranco Vitiello, Stefano Centanni

Summary: The post hoc analysis from the Italian study ANANKE aimed to define the clinical features and effectiveness of benralizumab in the BEC 300-450 cells/mm3 subset of patients. Results showed that patients in this subset had similar improvements in exacerbation rate, asthma control, lung function, and corticosteroid use after 48 weeks of benralizumab treatment compared to the total population.

JOURNAL OF ASTHMA AND ALLERGY (2022)

Review Biochemistry & Molecular Biology

Switching Biological Therapies in Severe Asthma

Giulia Scioscia, Santi Nolasco, Raffaele Campisi, Carla Maria Irene Quarato, Cristiano Caruso, Corrado Pelaia, Andrea Portacci, Claudia Crimi

Summary: Currently, Italy offers three classes of monoclonal antibodies for severe asthma treatment: anti-IgE (Omalizumab), anti-IL-5/anti-IL-5Ra (Mepolizumab and Benralizumab), and anti-IL-4Ra (Dupilumab). Studies have been conducted to determine their efficacy and identify predictors of treatment outcomes. Switching to another monoclonal antibody is recommended if there are no benefits. The choice of treatment should consider the patient's clinical history, biomarkers, and comorbidities.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Allergy

Evaluation and Updated Classification of Acute Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAID-Exacerbated or-Induced Food Allergy

Antonino Romano, Francesco Gaeta, Cristiano Caruso, Alessandro Fiocchi, Rocco Luigi Valluzzi

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Article Biology

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Andrea Giovanni Ledda, Giulia Costanzo, Giada Sambugaro, Cristiano Caruso, Martina Bullita, Maria Luisa Di Martino, Paolo Serra, Davide Firinu, Stefano Del Giacco

Summary: This study investigated the effects of dupilumab on inflammatory biomarkers in patients with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The results showed that after treatment with dupilumab, levels of eosinophils and eosinophil cationic protein initially increased and then gradually declined, returning to baseline levels. Additionally, serum total IgE and fractional exhaled nitric oxide levels decreased over time, while FEV1 and FEV1% improved significantly.

LIFE-BASEL (2023)

Article Respiratory System

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Alessandra Vultaggio, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Maria D'Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Marco Benci, Silvia Boarino, Jan Walter Schroeder

Summary: In this study, the long-term effects of benralizumab in patients with severe eosinophilic asthma (SEA) were evaluated. The results showed that treatment with benralizumab for up to 96 weeks resulted in significant improvements in asthma symptoms, lung function, and reduced exacerbations and oral corticosteroid use in SEA patients. Overall, benralizumab demonstrated remarkable efficacy in treating SEA.

RESPIRATORY RESEARCH (2023)

Meeting Abstract Allergy

Detection Of Serum Specific IgE By Fluoro-Enzyme Immunoassay For The Diagnosis Of Immediate Allergic Reactions To Penicillins

Adriana Ariza Veguillas, Gador Bogas Herrera, Francesco Gaeta, Maria Salas, Rocco Valluzzi, Marina Labella, Natalia Perez-Sanchez, Cristiano Caruso, Ana Molina Bueno, Tahia Fernandez, Cristobalina Mayorga, Maria Jose Torres, Antonino Romano

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Review Allergy

Nasal Cytology: A Easy Diagnostic Tool in Precision Medicine for Inflammation in Epithelial Barrier Damage in the Nose. A Perspective Mini Review

Cristiano Caruso, Rossana Giancaspro, Giuseppe Guida, Alberto Macchi, Massimo Landi, Enrico Heffler, Matteo Gelardi

Summary: Nasal cytology is a non-invasive and repeatable diagnostic tool that can be used to evaluate biomarkers in non-allergic rhinitis and chronic rhinosinusitis forms, and predict the prognostic index of recurrence of nasal polyposis.

FRONTIERS IN ALLERGY (2022)

Article Otorhinolaryngology

Chronic rhinosinusitis with nasal polyps: how to identify eligible patients for biologics in clinical practice

Matteo Gelardi, Corso Bocciolini, Mario Notargiacomo, Irene Schiavetti, Cristiano Lingua, Pietro Pecoraro, Lucia Iannuzzi, Vitaliano Antonio Quaranta, Rossana Giancaspro, Gianluca Ronca, Michele Cassano, Giorgio Ciprandi

Summary: This study compared three severity measures for chronic rhinosinusitis with nasal polyps and found that the combined use of nasal polyp score, sinonasal outcome test, and clinical-cytological grading is preferable for identifying patients eligible for biological therapy.

ACTA OTORHINOLARYNGOLOGICA ITALICA (2022)

Article Respiratory System

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Francesco Menzella, Elena Bargagli, Maria Aliani, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Cristiano Caruso, Stefano Centanni, Maria D'Amato, Stefano Del Giacco, Fausto De Michele, Fabiano Di Marco, Elide Anna Pastorello, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Alessandra Vultaggio, Lucia Simoni, Alessandra Ori, Silvia Boarino, Gianfranco Vitiello, Elena Altieri, Giorgio Walter Canonica

Summary: This study examined the baseline characteristics and therapy effectiveness of patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting. The results showed that benralizumab treatment significantly reduced exacerbations and the use of oral corticosteroids, and improved lung function and asthma control.

RESPIRATORY RESEARCH (2022)

暂无数据